view high-bandwidth site

Media Center

Wave 80 Presents Latest Results on Type 1 Diabetes at 2019 American Diabetes Association meeting

Multiplexed detection and quantitation of T1D-relevant autoantibodies holds significant promise for improving patient outcomes.

San Francisco, California, June 12, 2019—At the 2019 American Diabetes Association meeting, Wave 80 presented the latest results on clinical sample testing using its high-performance assay technology to detect and quantify panels of autoantibodies of critical relevance to type 1 diabetes disease progression. The advance is particularly important in light of the increasingly strong pipeline of disease-modifying interventions for T1D.


First Liquid Micropiston Technology Patent Issued to Wave 80

Grant by United States Patent and Trademark Office covers groundbreaking Wave 80 technology for high-performance molecular assays, liquid biopsy, and other applications.

San Francisco, California, June 12, 2018—A major new patent covering Wave 80 technology has been issued by the U.S. Patent and Trademark Office. The patent's claims encompass core components of Wave 80's liquid micropiston technology, the technology at the heart of Wave 80's revolutionary EOSCAPE platform, developed under contract with the U.S. National Institutes of Health as a powerful new tool for understanding key aspects of HIV/AIDS pathogenesis and for improving HIV/AIDS patient outcomes in high-disease-burden settings.


Wave 80 Founder and Leading Kenyan Pharmaceutical Executive Give Joint Keynote Speech at Major Tuberculosis Meeting

Dan Laser shares CPTR stage with UCL's Palu Dhanani to deliver powerful message on the vital importance of inter-organizational collaboration to address high-unmet-need areas in global health

Washington, DC, April 6, 2016—At a major gathering of leaders in the tuberculosis field, held in Washington DC, Wave 80 founder and Board of Directors chairman Dr. Daniel Laser was joined by Palu Dhanani, Managing Director of leading Kenyan pharmaceutical firm UCL, in giving a joint keynote address on best practices in life sciences joint ventures for high-disease-burden countries.


Wave 80's Innovative Approach to Tuberculosis Sequencing Featured in Clinical Infectious Disease Special Issue

Liquid micropiston-based sequencing technology meet emerging needs around multi-drug resistant strains

San Francisco, California, October 15, 2015—A special issue of leading infectious diseases journal Clinical Infectious Diseases, published this month, features advances in tuberculosis sequencing developed by Wave 80 scientists.


$3.9 million for EOSCAPE-HIV rollout allocated by UNITAID

Strong NGO support cited for unique system's extraordinary potential to significantly reduce rates of transmission

San Francisco, California and Geneva, Switzerland, June 4, 2015—The Executive Board of UNITAID, an international organization that invests in innovations to prevent, diagnose and treat HIV/AIDS, tuberculosis and malaria more quickly, affordably and effectively, announced a draft resolution to provide $3.9 million to support rapid rollout of Wave 80's EOSCAPE-HIV in high-disease-burden countries.


Featured Presentation at Sample Preparation Conference Highlights Wave 80’s Technological Leadership

Dr. Shan Gao, a senior member of Wave 80’s technical staff, to speak on high-efficiency extraction of genomic material from challenging samples without centrifugation.

San Diego, California, April 18, 2013—The Sample Prep 2013 conference, to be held on May 9-10, will feature an invited talk by Wave 80’s Dr. Shan Gao, conference organizers have announced.

The presentation will highlight recent evaluation data from sample preparation modules built into disposable cartridges used with the company’s EOSCAPE next-generation molecular diagnostics platform.


Wave 80 to Unveil Latest Advances in High-Speed Microfluidics Technology at SemiCon China

Semiconductor manufacturing processes leveraged in production of unique fluidic actuator chips.

San Francisco, California, March 1, 2013—Dr. Daniel Laser, Wave 80’s Chief Executive Officer and President, will discuss major recent advances in the company’s bioassay technology as part of an invited talk at the upcoming Semicon China 2014 conference, the company announced today. The conference, to be held in Shanghai from March 18-20, 2013, is a leading international forum for new product releases and announcements in the semiconductor and solar power sectors.


New Journal Article Highlights Challenges, Opportunities for Next-Generation Point-of-Care Testing Technologies

Dr. Laura Mazzola, Wave 80’s Senior Vice President of Global Initiatives, co-authors analysis of impact and opportunities for POC diagnostics.

San Francisco, California, March 7, 2012. A new scientific publication appearing today highlights the promise of emerging point-of-care testing technologies to improve individual patient outcomes and public health, while also shedding light on the barriers posed by a host of barriers ranging from global regulatory process discord to outdated reimbursement practices to infrastructure-related product distribution inefficiencies in developing countries.


Wave 80 awarded $7.5 million NIH contract for HIV rapid virus testing

Next-generation point-of-care molecular diagnostic system meets challenges of detecting acute infections, monitoring recipients of candidate vaccines, and diagnosing infants born to HIV-infected mothers.

San Francisco, California, October 28 2009. Wave 80 Biosciences, Inc. today announced that it has been awarded a USD 7.5 million contract (HHSN272200900029C) by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, Department of Health and Human Services, for rapid HIV/AIDS nucleic acid testing systems for use in low resource settings.


Wave 80 chief executive to address microsystems commercialization conference in Chongqing, China

Talk will highlight evolving challenges and opportunities in global health.

San Francisco, California, October 14 2009. Daniel J. Laser, Ph.D., Wave 80's Chief Executive Officer and President, will speak at the 3rd International Workshop on Innovation and Commercialization of Micro and Nano Technology (ICMAN 2009), the company announced today.


Wave 80, Magnisense partner in infectious disease diagnostics and patient monitoring

Collaboration to explore new ways of using magnetic detection in high-performance enclosed-cartridge-format assays.

Paris, France and San Francisco, California, March 5, 2009. Magnisense ( and Wave 80 Biosciences ( today announced the establishment of a new strategic partnership to explore synergies between the companies’ industry-leading technology platforms, MIAtek™ magnetic detection technology and SCATM assay cartridge technology.


Wave 80 presents poster at multiple sclerosis meeting

Exploring new methods of optimizing therapies.

San Francisco, California, January 3, 2009. Wave 80's Senior Director of Applied Cell Physiology, Dr. Andrew Arsham, will present a poster at the upcoming Keystone Symposium on Multiple Scleroris, to be held in Santa Fe, New Mexico from January 21-26, 2009, the company announced today.


Wave 80 initiates new program in biomarker-based stroke patient stratification

New approach to guiding therapy holds promise for improving patient outcomes in ischemic stroke.

San Francisco, CA, July 9, 2008 – Researchers at Wave 80 have commenced a new program exploring the use of circulating biomarkers to inform clinical decisionmaking in acute stroke by predicting which patients are most likely to benefit from current and emerging treatments, the company announced today.

"Acute ischemic stroke is an area of high unmet need," said Daniel Laser, Ph.D., Wave 80's CEO. "This program leverages key elements of the biomarker measurement technology platform Wave 80 developed for the U.S. military to tackle the extraordinary challenge of guiding stroke therapy within the narrow window of opportunity when administering therapy is most effective."


Wave 80, Siemens team up on HIV viral load measurement

With NIH support, initiative seeks to develop innovative tools for guiding antiretroviral therapy

San Francisco, California and Tarrytown, New York, October 19, 2007 – Targeting a major area of need in the global fight against HIV/AIDS, Wave 80 and Siemens Medical Solutions Diagnostics today announced the beginning of a new research initiative focused on technologies to complement pharmaceutical strategies for helping patients diagnosed with HIV lead longer, more productive lives.


Wave 80 malaria diagnostic selected for oral presentation at prestigious Oak Ridge conference

Emerging technologies forum will showcase research on ultraminature device for multiplexed measurement of malarial disease markers in fingerstick blood samples

San Francisco, California, March 7, 2007 – Daniel Laser,, Ph.D., Wave 80’s CEO and President, will give an invited talk at the 39th Annual Oak Ridge conference: Harnessing New Technology for Clinical Diagnostics. The annual Oak Ridge meeting is sponsored by American Association for Clinical Chemistry and brings together thought leaders in diagnostics methods and instrumentation. The 2007 meeting will be held in St. Louis, Missouri on April 18-19, 2007.